H Barton Grossman1, Joaquim Bellmunt2, Peter C Black3. 1. MD Anderson Cancer Center, University of Texas, Houston, TX, USA. Electronic address: hbgrossman@MDAnderson.org. 2. Dana Farber Cancer Institute, Boston, MA, USA. 3. The University of British Columbia, Vancouver, Canada.
Abstract
Current guidelines recommend cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy as the preferred treatment of muscle-invasive bladder cancer. Nevertheless, for multiple reasons compliance with this guideline recommendation is low. This is particularly evident in clinical T2 bladder cancer, where controversy exists regarding the role of proceeding with radical cystectomy alone. Novel biomarkers such as molecular phenotype and DNA damage repair and response gene alterations may be able to predict who will respond to cisplatin-based neoadjuvant chemotherapy. This clinical problem is discussed, and a recommendation is made given the current state of the art. PATIENT SUMMARY: Neoadjuvant chemotherapy improves survival for patients with muscle-invasive bladder cancer. In the future, perhaps validated biomarkers may predict who should and should not receive this treatment.
Current guidelines recommend cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy as the preferred treatment of muscle-invasive bladder cancer. Nevertheless, for multiple reasons compliance with this guideline recommendation is low. This is particularly evident in clinical T2 bladder cancer, where controversy exists regarding the role of proceeding with radical cystectomy alone. Novel biomarkers such as molecular phenotype and DNA damage repair and response gene alterations may be able to predict who will respond to cisplatin-based neoadjuvant chemotherapy. This clinical problem is discussed, and a recommendation is made given the current state of the art. PATIENT SUMMARY: Neoadjuvant chemotherapy improves survival for patients with muscle-invasive bladder cancer. In the future, perhaps validated biomarkers may predict who should and should not receive this treatment.
Authors: Kimberly L Santucci; John M Baust; Kristi K Snyder; Robert G Van Buskirk; Aaron Katz; Anthony Corcoran; John G Baust Journal: Clin Res (Milpitas) Date: 2020-02-07
Authors: Satoshi Katayama; Victor M Schuettfort; Benjamin Pradere; Keiichiro Mori; Hadi Mostafaei; Fahad Quhal; Reza Sari Motlagh; Ekaterina Laukhtina; Nico C Grossmann; Abdulmajeed Aydh; Pawel Rajwa; Frederik König; Pierre I Karakiewicz; Martin Haydter; Marco Moschini; Mohammad Abufaraj; Yair Lotan; Richard K Lee; Quoc-Dien Trinh; Eva Compérat; Jeremy Teoh; Yasutomo Nasu; Shahrokh F Shariat Journal: J Cancer Res Clin Oncol Date: 2022-01-08 Impact factor: 4.322
Authors: Line H Dohn; Peter Thind; Lisbeth Salling; Henriette Lindberg; Sofie Oersted; Ib J Christensen; Ole D Laerum; Martin Illemann; Hans von der Maase; Gunilla Høyer-Hansen; Helle Pappot Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639